Search
On September 16, 2026, Anew Labs, an AI-driven pharmaceutical company, officially declared the successful closure of its independent Series A funding round, amassing a substantial total of $290 million. This pivotal financing event attracted the participation of esteemed investment entities, including Sequoia China, Hillhouse Capital, IDG Capital, Five Sources Capital, and Gaorong Capital, alongside a number of prominent domestic pharmaceutical conglomerates. Anew Labs emerged as an autonomous entity in June of the same year, following its strategic divestiture from ByteDance's AI pharmaceutical division. The transition encompassed the seamless integration of the core team, advanced algorithm platform, and pre-existing pipeline assets into the newly established company.
-
C114 Communication Network -
Communication Home
